New combo aims to stop leukemia relapse in High-Risk patients
NCT ID NCT05361057
First seen Jan 09, 2026 · Last updated May 23, 2026 · Updated 17 times
Summary
This study tested whether a combination of venetoclax and azacytidine (or a DA regimen) could prevent relapse in adults with acute myeloid leukemia (AML) who still had measurable disease (MRD positive) after standard chemotherapy. The goal was to extend the time patients stayed in remission. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HBDH
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.